An observational study in Myocardial Infarction, Atheroma and Cholesterol, sponsored by Elsan. Recruiting at 1 site in France. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by Elsan · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 168 studies in Myocardial Infarction with a site in France — 22 open to participants now, 31 under way, 7 of them phase 3. Myocardial Infarction · France.
Among the 168 studies in Myocardial Infarction with a site in France, this one is the 24th largest by planned enrollment of the 54 observational ones that give a count, is one of 11 that started in 2021, is one of 54 observational ones, reaches primary completion later than 4 of the 30 other live ones, and was the 163rd registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →22 of the 168 studies in Myocardial Infarction with a site in France are open now. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–80
French Cardiology Society · Sites in France
Ages 18–60 · Women only
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
CellProthera · Sites in France, United Kingdom
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
168 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 14 · Phase 3 42 · Phase 4 14
First in 2002; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 568 across 814 observational studies indexed under Myocardial Infarction.
Median enrollment 332 across the 114 interventional studies, 756 across the 54 observational. Of the 124 that completed or were terminated, 24 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 168 have an industry lead sponsor. The 10 most frequent:
Elsan is the lead sponsor of 68 studies on the registry; 35 are open to participants now.
Elsan has 1 study filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
8 of the studies in Myocardial Infarction with a site in France that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT05577988Phase 3Assistance Publique - Hôpitaux de ParisAssessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome | 2027-06 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT02762162Action, FranceRegistry of Coronary Artery Ill Patients With Platelet Test Results | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 168 studies in Myocardial Infarction with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To prevent myocardial infarction ( MI), coronary atheroma development by LDL-cholesterol deposition in the arterial wall is the basis. Since atheromatous plaques develop slowly before becoming symptomatic, their early detection in asymptomatic patients and the implementation of an effective strategy to prevent their progression constitute the most promising primary prevention strategy. In younger subjects, the main modifiable pro-atheromatous factors are smoking and an excessively high LDL-C level, partly genetically predetermined, but also favored by a diet too rich in saturated fats and a lack of physical activity. In the French national MI registry, the average age of patients is 62 years (Arch Cardiovasc Dis 2021 Oct;114(10):647-655). Half of MIs therefore occur at working age due to rupture of atheromatous plaques, which had developed during the months/years preceding the acute event.
According to the latest recommendations of the European Society of Cardiology (ESC) on CV prevention published in August 2021, the visualization of coronary or carotid atheromatous plaques justifies considering the patient as having atherosclerotic cardiovascular disease (ASCVD), and automatically places them in the "very high CV risk" category, with an LDL-cholesterol target of \<0.55 g/L. However, these recommendations do not clearly define the criteria justifying the use of imaging in asymptomatic patients.
In current practice, CV risk stratification for asymptomatic patients with no prior CV disease is currently based on risk calculation using the European "SCORE 2" algorithm, available online. It allows the calculation of the absolute risk in % of occurrence of a fatal or non-fatal CV event (myocardial infarction, stroke) over 10 years.
The main objective of this study is to describe patients reclassified as "very high CV risk" following the detection of atheroma plaques formed in relation to their risk level estimated by SCORE2.
It is a national, single-center, retrospective and prospective study on the collection of routine care data.
Cardiology team of the Poitiers polyclinic (France)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: SCORE2
the European algorithm "SCORE 2", available online (figure 1). It allows the calculation of the absolute risk in % of occurrence of a fatal or non-fatal CV event (myocardial infarction, stroke) over 10 years.
Very high risk cardiovascular (yes/no)
Patients reclassified as "very high CV risk" (Yes/No) compared to the risk level estimated by SCORE2. SCORE2 is determined by an online calculator from the European Society of Cardiology (ESC).
Time frame: 12 months
Started Sep 2021 (actual). Primary completion is estimated for Dec 2025, 51 months after the start.
Of 298 non-industry observational studies under Myocardial Infarction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 140. This study's planned 51 months is close to that.
Counting every sponsor, half of 335 studies reached it within 48 months; a quarter within 18 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Elsan